Advertisement
YOU ARE HERE: LAT HomeCollectionsCortex Pharmaceuticals Inc
IN THE NEWS

Cortex Pharmaceuticals Inc

BUSINESS
September 30, 1999
The Irvine drug development company reported a net loss of $468,728, or 3 cents a share, for the fourth fiscal quarter, compared with a net loss of $1.2 million, or 12 cents a share, for the year-earlier period. The company had operating revenue of $690,000 for the quarter ended June 30. No revenue was reported for the fourth quarter last year. For the year, the company posted a net loss of $1.6 million, or 12 cents a share, compared with a net loss of $5.
Advertisement
BUSINESS
May 14, 1999
Cortex Pharmaceuticals Inc.: The Irvine developer of drug therapies for neurological and psychiatric disorders reported net income of $979,224, or 6 cents a share, for the third fiscal quarter, contrasted with a net loss of $1.5 million, or 15 cents a share, for the corresponding previous-year period. Revenue for the quarter ended March 31 rose to $2.5 million from $80,000.
BUSINESS
March 18, 1999
Cortex Pharmaceuticals Inc. said Wednesday its stock has been removed from the Nasdaq SmallCap market. The shares, which have been trading below $1 since mid-October, will be traded on the low-profile over-the-counter market. The stock closed Wednesday at 44 cents a share, unchanged. Irvine-based Cortex, a developer of therapies for neurological and psychiatric disorders, has lost money every year this decade.
BUSINESS
December 1, 1998 | BARBARA MARSH, Barbara Marsh covers health care for The Times. She can be reached at (714) 966-7762 and at barbara.marsh@latimes.com
It may not be much, but it's the thought that counts for Cortex Pharmaceuticals Inc. The tiny Irvine developer of drug therapies for neurological and psychiatric disorders just landed a $100,000 grant from the National Institutes of Health to help develop a treatment for schizophrenia. The money will help fund the company's search for new compounds that could be administered once a day.
BUSINESS
November 9, 1998
Irvine-based Cortex Pharmaceuticals Inc. posted a loss of $1.2 million, or 12 cents a share, for the fiscal first quarter ended Sept. 30, compared with a loss of $1.3 million, or 14 cents a share, for the same period a year ago. The company reported no revenue.
BUSINESS
October 24, 1998 | Barbara Marsh
Cortex Pharmaceuticals Inc., in danger of being delisted on the Nasdaq SmallCap Market, said Friday that it hopes to raise additional capital from prospective corporate partners. The Irvine-based developer of drug therapies for neurological and psychiatric disorders said in a statement that it is in talks with some investors but did not identify them. If the Nasdaq doesn't approve of Cortex's plan, the exchange will issue a formal notice of delisting.
BUSINESS
September 30, 1998
Cortex Pharmaceuticals Inc.: The Irvine developer of treatments for neurological and other psychiatric disorders posted a net loss of $1.17 million, or 12 cents a share, for the fourth quarter, ended June 30, compared with a net loss of $1.28 million, or 25 cents a share, for the same period a year earlier. The company reported no revenue. For the year, Cortex lost $5.3 million, or 55 cents a share, compared with a loss of $4.
BUSINESS
May 22, 1998 | Times Staff and Wire Reports
One day after doubling in price, NeoTherapeutics Inc.'s stock fell 31% Thursday after the biotechnology company elaborated on the risks and costs of its attempt to develop a drug for Alzheimer's disease. NeoTherapeutics fell $6 to $13.25 as 3.2 million shares were traded. On Wednesday, the stock doubled to $19.25 after reporting encouraging results for a treatment of Alzheimer's disease. Officials at the Irvine company said the results reported Wednesday had been disclosed previously.
BUSINESS
May 21, 1998 | LESLIE EARNEST, SPECIAL TO THE TIMES
Two Orange County drug developers became the latest firms swept up Wednesday in investors' euphoria over companies working on treatments for a variety of serious diseases. NeoTherapeutics Inc.'s stock more than doubled to $19.25 a share from $9.60, making it the biggest percentage gainer in U.S. markets, after the Irvine company reported encouraging results for a treatment for Alzheimer's disease. Earlier in the session, the stock hit an all-time high of $21.
Los Angeles Times Articles
|